Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax
Shifting mitochondrial dynamics toward fusion by targeting the MARCH5-MFN2 axis impairs ETC and OXPHOS, thereby sensitizing MM cells to venetoclax. These findings provide preclinical evidence for the potential therapeutic use of MFN2 inducers to enhance venetoclax responsiveness of MM patients.
Authors
- Roberta Torcasio
- Maria Eugenia Gallo Cantafio (ORCID: https://orcid.org/0009-0009-9937-0565)
- Nicola Cuscino (ORCID: https://orcid.org/0000-0002-2790-7257)
- Maria Mesuraca (ORCID: https://orcid.org/0000-0002-5455-168X)
- Alessia Gallo (ORCID: https://orcid.org/0000-0001-6737-9770)
- Ida Perrotta (ORCID: https://orcid.org/0000-0002-9061-9776)
- Giuseppe Viglietto (ORCID: https://orcid.org/0000-0003-2327-7515)
- Pierpaolo Murfone
- Ludovica Ganino
- Ilenia Valentino
- Nicola Amodio (ORCID: https://orcid.org/0000-0002-1345-4410)
- Federico Tallarigo
Institutions
- Harvard University (US)
- Magna Graecia University (IT)
- Istituto S.Anna Crotone (IT)
- Dana-Farber Cancer Institute (US)
- Ospedale Annunziata di Cosenza (IT)
- University of Calabria (IT)
- Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IT)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1186/s12967-025-06942-0
- Citations
- 3
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.42